These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36399219)

  • 41. The CITIMEM study: A pilot study. Optimizing pharmacological treatment in dementia.
    Gareri P; Cotroneo AM; Orsitto G; Putignano S
    Arch Gerontol Geriatr; 2020; 89():104073. PubMed ID: 32447126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment.
    Meghdadi AH; Stevanović Karić M; McConnell M; Rupp G; Richard C; Hamilton J; Salat D; Berka C
    PLoS One; 2021; 16(2):e0244180. PubMed ID: 33544703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Global dynamical analysis of the EEG in Alzheimer's disease: frequency-specific changes of functional interactions.
    Jelles B; Scheltens P; van der Flier WM; Jonkman EJ; da Silva FH; Stam CJ
    Clin Neurophysiol; 2008 Apr; 119(4):837-41. PubMed ID: 18258479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls.
    Dauwan M; van Dellen E; van Boxtel L; van Straaten ECW; de Waal H; Lemstra AW; Gouw AA; van der Flier WM; Scheltens P; Sommer IE; Stam CJ
    Neurobiol Aging; 2016 May; 41():122-129. PubMed ID: 27103525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease.
    Saeedi M; Mehranfar F
    Recent Pat Biotechnol; 2022; 16(2):102-121. PubMed ID: 35236274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploration of EEG features of Alzheimer's disease using continuous wavelet transform.
    Ghorbanian P; Devilbiss DM; Hess T; Bernstein A; Simon AJ; Ashrafiuon H
    Med Biol Eng Comput; 2015 Sep; 53(9):843-55. PubMed ID: 25863694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of PICALM and CLU risk variants on beta EEG activity in Alzheimer's disease patients.
    Maturana-Candelas A; Gómez C; Poza J; Rodríguez-González V; Pablo VG; Lopes AM; Pinto N; Hornero R
    Sci Rep; 2021 Oct; 11(1):20465. PubMed ID: 34650147
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.
    Schmidt R; Hofer E; Bouwman FH; Buerger K; Cordonnier C; Fladby T; Galimberti D; Georges J; Heneka MT; Hort J; Laczó J; Molinuevo JL; O'Brien JT; Religa D; Scheltens P; Schott JM; Sorbi S
    Eur J Neurol; 2015 Jun; 22(6):889-98. PubMed ID: 25808982
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data.
    Dysken MW; Guarino PD; Vertrees JE; Asthana S; Sano M; Llorente M; Pallaki M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Carney S; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Vatassery G
    Alzheimers Dement; 2014 Jan; 10(1):36-44. PubMed ID: 23583234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
    Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
    Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination of Memantine and 6-Chlorotacrine as Novel Multi-Target Compound against Alzheimer's Disease.
    Kaniakova M; Nepovimova E; Kleteckova L; Skrenkova K; Holubova K; Chrienova Z; Hepnarova V; Kucera T; Kobrlova T; Vales K; Korabecny J; Soukup O; Horak M
    Curr Alzheimer Res; 2019; 16(9):821-833. PubMed ID: 30819076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Holmes C; Jones M; Jones R; Livingston G; McKeith I; Mittler P; Passmore P; Ritchie C; Robinson L; Sampson EL; Taylor JP; Thomas A; Burns A
    J Psychopharmacol; 2017 Feb; 31(2):147-168. PubMed ID: 28103749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Memantine in Alzheimer's disease: experience in an Alzheimer's disease assessment unit.
    Sinforiani E; Pasotti C; Chiapella L; Malinverni P; Zucchella C
    Aging Clin Exp Res; 2012 Apr; 24(2):193-6. PubMed ID: 22842837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease.
    Glynn-Servedio BE; Ranola TS
    Consult Pharm; 2017 Sep; 32(9):511-518. PubMed ID: 28855009
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Memantine in moderate-to-severe Alzheimer's disease.
    Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ;
    N Engl J Med; 2003 Apr; 348(14):1333-41. PubMed ID: 12672860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topological Pattern Recognition of Severe Alzheimer's Disease via Regularized Supervised Learning of EEG Complexity.
    Fan M; Yang AC; Fuh JL; Chou CA
    Front Neurosci; 2018; 12():685. PubMed ID: 30337850
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.
    Uddin MS; Al Mamun A; Kabir MT; Ashraf GM; Bin-Jumah MN; Abdel-Daim MM
    Mol Neurobiol; 2021 Jan; 58(1):281-303. PubMed ID: 32935230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.